The earnings call reflects a positive outlook due to the significant milestone of FDA marketing authorization for ProSense, opening up substantial market opportunities and driving global interest. Financially, the company has improved its cash position, although revenue and gross margin have seen declines. Overall, the highlights of strategic achievements and market potential outweigh the current financial challenges.

Company Guidance

During the recent conference call, IceCure Medical provided several key metrics that underscore their strategic growth trajectory following the FDA's marketing authorization for their ProSense system, specifically for treating low-risk breast cancer in women aged 70 and older with tumors up to 1.5 centimeters. This decision targets an estimated addressable market of 200,000 patients annually in the U.S., including 46,000 women diagnosed with low-risk breast cancer, 88,000 patients ineligible or unwilling to undergo surgery, and 63,000 women with benign breast tumors opting for non-surgical treatment. Financially, for the nine months ending September 30, 2025, IceCure reported $2.1 million in revenue, a decrease from $2.4 million in the same period in 2024, attributed to sales fluctuations in Japan and other regions. Despite this, gross profit improved to $626,000 with a gross margin of 30%, compared to 43% last year. The company also highlighted a net loss of $10.8 million, closely aligned with the previous year's loss. IceCure's cash position was strengthened by a $10 million rights offering, enhancing their capability to support commercialization and strategic initiatives. The company plans to expand its U.S. commercial footprint with a post-market study involving 30 clinical sites, expecting to enroll the first patient by summer 2026, bolstered by an anticipated CPT code reimbursement increase to over $4,000 in early 2026. Globally, IceCure aims to capitalize on FDA approval to drive international adoption, with ProSense recently gaining approval in Switzerland and ongoing regulatory efforts in Japan through their partnership with Terumo Corporation.

FDA Marketing Authorization for ProSense

The FDA granted marketing authorization for IceCure Medical's ProSense system to treat low-risk breast cancer, positioning the company at the forefront of minimally invasive breast cancer care.

Significant Addressable Market

ProSense addresses a potential market of approximately 200,000 patients annually in the U.S., including 46,000 women over 70 diagnosed with low-risk breast cancer, 88,000 patients not eligible for surgery, and 63,000 women with benign breast tumors.

International Expansion and Interest

Global interest is growing following FDA approval, with recent regulatory approval in Switzerland and plans for expansion in Japan with Terumo Corporation.

Financial Position Strengthened

IceCure Medical raised $10 million from a rights offering and $5.87 million from a market offering, bringing the cash balance to $11.8 million as of October 31, 2025.

Operational Cost Optimization

Total operating expenses decreased to $11.5 million from $12.2 million, reflecting efforts to optimize spending while executing commercial and regulatory strategies.

Icecure Medical (ICCM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ICCM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 26, 2026	2025 (Q4)	-0.04 / -	-0.078	―	―	―
Nov 19, 2025	2025 (Q3)	-0.05 / -0.06	-0.078	23.08% (+0.02)	―
Aug 13, 2025	2025 (Q2)	-0.06 / -0.06	-0.059	-1.69% (>-0.01)	―
May 28, 2025	2025 (Q1)	-0.08 / -0.06	-0.078	24.36% (+0.02)	―
Mar 27, 2025	2024 (Q4)	-0.07 / -0.08	-0.059	-32.20% (-0.02)	―
Nov 26, 2024	2024 (Q3)	-0.07 / -0.08	-0.088	11.36% (<+0.01)	―
Aug 20, 2024	2024 (Q2)	-0.07 / -0.06	-0.088	32.95% (+0.03)	―
May 28, 2024	2024 (Q1)	- / -	-0.078	―	―
Apr 03, 2024	2023 (Q4)	-0.07 / -0.08	-0.078	0.00% (0.00)	―
Nov 15, 2023	2023 (Q3)	-0.09 / -0.09	-0.108	18.52% (+0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ICCM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 19, 2025	$0.72	$0.70	-3.19%
Aug 13, 2025	$0.82	$0.84	+2.44%
May 28, 2025	$1.11	$1.01	-8.84%
Mar 27, 2025	$1.12	$1.08	-3.04%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Icecure Medical Ltd. (ICCM) report earnings?

Icecure Medical Ltd. (ICCM) is schdueled to report earning on Mar 26, 2026, Before Open (Confirmed).

What is Icecure Medical Ltd. (ICCM) earnings time?

Icecure Medical Ltd. (ICCM) earnings time is at Mar 26, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ICCM EPS forecast?

ICCM EPS forecast for the fiscal quarter 2025 (Q4) is -0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing